Immune Responses to Novel Adenovirus Type 26 and Modified Vaccinia Virus Ankara–Vectored Ebola Vaccines at 1 Year

The Ebola virus vaccine strategies evaluated by the WHO in response to the recent outbreak in West Africa included a heterologous prime/boost schedule of the adenovirus type 26 vector vaccine encoding Ebola virus glycoprotein (Ad26.ZEBOV) and the modified vaccinia virus Ankara vector vaccine, encoding glycoproteins from Ebola virus, Sudan virus, Marburg virus, and Tai Forest virus nucleoprotein (MVA-BN-Filo). This schedule has been shown to induce immune responses that persist for 8-months post priming immunization, with 100% of vaccine recipients retaining Ebola virus glycoprotein-specific antibodies.